BPC-157 Side Effects: What the Research Actually Shows

BPC-157 is the most talked-about research peptide in the world, and “BPC-157 side effects” is one of the most searched questions about it. The answers online range from “none at all” to alarming warnings, usually with no evidence either way. This guide takes a different approach. It sets out exactly what has been studied, in what kind of research, what was found about safety, what has not been studied, and where the genuine open questions are, citing the research throughout.

This is an educational overview of research findings, not medical advice. Crown Peptides supplies BPC-157 for laboratory research use only; it is not a licensed medicine and is not supplied for human use.

The Short Answer

In animal research, BPC-157 has been studied for decades, and many studies report no obvious toxic effects. In people, there is very little controlled evidence of any kind: a tiny pilot safety study, some small uncontrolled reports and no large randomised trials. That means its side effect profile in humans is simply not established. The absence of reported side effects in small studies is not the same as proof of safety, and several reviews have highlighted theoretical concerns that have not been ruled out.

What BPC-157 Is

BPC-157 is a 15-amino-acid peptide derived from a protein found in human gastric juice. It was developed and studied for decades by Predrag Sikirić’s group at the University of Zagreb, and it is often called the stable gastric pentadecapeptide because it survives the acidic conditions of the stomach. Its research spans the gut, tendons, ligaments, muscle, bone, skin, blood vessels and the nervous system. Our BPC-157 guide covers that research in depth.

How it is thought to work

Research has linked BPC-157 to several processes involved in repair. A 2017 study in the Journal of Molecular Medicine found it increased blood vessel formation and activated VEGFR2, the main receptor for vascular endothelial growth factor (PMID: 27847966). A 2011 study found it promoted the outgrowth, survival and migration of tendon fibroblasts through the FAK-paxillin pathway (PMID: 21030672). Understanding these mechanisms matters for safety, because the same processes that support repair are the ones that raise theoretical questions.

A Short History of BPC-157

BPC-157’s story began in the early 1990s in Zagreb, where Sikirić’s group was studying a protein fraction from gastric juice that seemed to protect the stomach lining. They identified a 15-amino-acid sequence within it, which they called body protection compound 157, and began testing it in models of stomach ulcers. Over the following decades, the research spread from the gut to tendons, ligaments, muscle, bone, blood vessels, the liver and the brain, producing one of the largest animal research records of any research peptide.

In the 2010s, BPC-157 began to attract interest far beyond the laboratory, particularly in sports and fitness communities, long before any human trials had been completed. That gap, between enormous public interest and very limited human evidence, is the root of most of the confusion about its side effects today.

What Animal Research Shows About Safety

Decades of studies

BPC-157 has been tested in a very large number of animal models, mostly rats and mice, across many tissues and routes of administration. A 2021 review in Frontiers in Pharmacology by Seiwerth, Sikirić and colleagues summarised its wound healing research across many models (PMID: 34267654, PMC8275860). The research group has consistently reported a lack of obvious toxicity in these studies.

Tendon research as an example

In a 2003 study in the Journal of Orthopaedic Research, BPC-157 accelerated healing of cut Achilles tendons in rats, improving biomechanical, functional and microscopic measures, and stimulated the growth of tendon cells in the laboratory (PMID: 14554208). Studies like this report the outcome being studied but are not designed as full safety studies.

The limits of the animal evidence

Most animal research on BPC-157 was designed to test whether it helps healing, not to hunt systematically for harm. Formal toxicology packages, of the kind required before a medicine enters human trials, are not widely published. Much of the research also comes from one group, which is a recognised limitation that reviewers have pointed out. Independent replication by other laboratories is an important part of establishing any compound’s profile.

What Human Research Shows

A pilot safety study

In 2025, a pilot study in Alternative Therapies in Health and Medicine reported intravenous infusion of BPC-157 in two healthy adults, measuring markers of heart, liver, kidney, thyroid and blood sugar function (PMID: 40131143). No measurable effects on those markers and no side effects were reported. With only two participants, the study can show that no obvious immediate problems appeared, but it cannot establish safety.

Small uncontrolled reports

A 2021 retrospective report in the same journal described 16 patients with various types of knee pain treated with BPC-157, alone or combined with thymosin beta-4, most of whom reported improvement (PMID: 34324435). It had no control group and relied on patient recall, so it cannot separate a real effect from placebo or natural recovery, and it was not designed to assess side effects systematically.

What systematic reviews concluded

A 2025 systematic review in HSS Journal examined the emerging use of BPC-157 in orthopaedic sports medicine and found the human evidence very limited (PMID: 40756949, PMC12313605). A 2025 narrative review in Current Reviews in Musculoskeletal Medicine, titled “Regeneration or Risk?”, reached a similar view: promising preclinical findings, a near-absence of rigorous human data, and unresolved safety questions (PMID: 40789979, PMC12446177).

The Open Questions Researchers Raise

Reviews of BPC-157 consistently highlight several questions that have not been answered.

Blood vessel growth

BPC-157’s link to blood vessel growth through VEGFR2 is central to its repair research. Blood vessel growth is also something tumours depend on. There is no evidence that BPC-157 causes cancer, but the theoretical question of whether promoting blood vessel growth could support existing unwanted growth has not been studied in the long-term human research that would be needed to answer it.

Long-term effects

There are no long-term human studies. Any effects that develop over months or years are unknown.

Interactions

BPC-157 has been reported in animal studies to interact with several signalling systems, including nitric oxide and the dopamine and serotonin systems. How it might interact with medicines in people has not been studied.

Specific populations

There are no data on pregnancy, breastfeeding, children or people with existing medical conditions.

Product quality

Because BPC-157 is widely sold outside regulated channels, the quality of what people actually obtain is a major unknown. Studies of unregulated peptide products have found very low purity and toxic metal contamination (PMID: 30029448). Any side effects from such products may be caused by impurities rather than by BPC-157 itself.

Claims You May See Online, Examined

Online discussions of BPC-157 are full of anecdotal reports, both positive and negative. It is worth being clear about what those can and cannot tell us.

Anecdotes are not evidence of cause

Individuals sometimes describe symptoms such as nausea, dizziness, headaches or changes in blood pressure after using unregulated products. Without controlled studies, there is no way to know whether these were caused by BPC-157, by impurities in the product, by something else entirely or by chance. The same applies to reports of dramatic benefits.

The product problem

Because most people discussing BPC-157 online are describing products of unknown origin and quality, their experiences may say more about those products than about the peptide itself.

What would settle it

Only properly designed human studies, with verified material, a placebo group and systematic recording of every adverse event, can separate real side effects from coincidence. Those studies have not yet been published.

How BPC-157’s Evidence Compares With Other Peptides

It helps to put BPC-157’s safety evidence in context. Licensed peptide medicines such as the GLP-1 drugs have trials involving thousands of people. Some research compounds, such as the growth hormone secretagogue Ipamorelin, reached formal phase 2 trials in over a hundred patients (PMID: 25331030). Thymosin beta-4, the basis of TB-500, has been tested in several formal clinical trials, including for eye and skin conditions. BPC-157 has a larger animal literature than many of these, but less formal human trial data. That places it in an unusual position: widely discussed, heavily studied in animals, and barely studied in people.

How to Read BPC-157 Research Critically

Check the species

Most BPC-157 findings come from rats and mice. Effects in rodents do not always translate to people.

Check the design

Look for control groups, randomisation and blinding. Uncontrolled reports are useful for generating questions but not for answering them.

Check who did the work

Much of the literature comes from a single research group. Independent replication by other laboratories strengthens any finding.

Check what was measured

A study designed to measure healing may not have looked for side effects at all. Absence of reported harm in such a study is not evidence of safety.

What Regulators Have Said

The US FDA

In 2023, the US FDA placed BPC-157 in a category of bulk substances that raised safety concerns for use by compounding pharmacies, citing among other things potential immunogenicity and a lack of human safety data. In July 2026, an FDA advisory committee voted 8 to 6 to recommend adding BPC-157 to the list of substances compounding pharmacies may use, reviewed for ulcerative colitis. The vote is advisory and requires further FDA action. Our article on the FDA advisory panel vote explains what it means.

In sport

The World Anti-Doping Agency names BPC-157 as an example of a non-approved substance on its Prohibited List, so it is banned for athletes subject to anti-doping rules.

In the UK

BPC-157 is not a controlled drug in the UK. It is not a licensed medicine. See is BPC-157 legal in the UK.

Why BPC-157’s Origin Matters for the Safety Question

BPC-157 is derived from a protein naturally present in human gastric juice, and supporters sometimes argue this makes it inherently safe. The reasoning deserves a closer look. The parent protein exists in the stomach at natural levels and in a natural context. BPC-157 itself is a synthetic 15-amino-acid fragment, and research products expose tissues to it in ways and amounts that never occur naturally. Its gastric origin is scientifically interesting, and it helps explain the peptide’s unusual stability, but it does not tell us how the isolated fragment behaves when supplied from outside over long periods. That question can only be answered by studying the fragment directly.

Timing: Short-Term vs Long-Term Unknowns

It is useful to separate two kinds of safety question. Short-term questions ask whether a compound causes immediate problems, such as reactions, changes in blood pressure or effects on organ function within days or weeks. The small human pilot addressed a narrow version of this question. Long-term questions ask whether effects build up or appear only after months or years of exposure, including effects on growth processes. Those questions have not been addressed in people at all. Animal studies of BPC-157 have mostly run for days to weeks, which is short relative to an animal’s lifespan, so even the animal evidence says relatively little about very long-term exposure.

What a Proper BPC-157 Safety Study Would Look Like

If researchers set out to answer the side effect question definitively, the design would be clear. Formal toxicology in two animal species, including long-term exposure and high amounts, would come first, along with studies of how the compound is absorbed, distributed and cleared. Human studies would then begin with small numbers of healthy volunteers under close monitoring, recording every symptom and measuring blood markers of liver, kidney, heart and blood sugar function. Larger randomised, placebo-controlled trials would follow, with enough participants and duration to detect uncommon effects, and with long-term follow-up. Every trial would use material verified by HPLC and mass spectrometry. That is the standard any compound must meet before its side effects can honestly be described as known.

Why “No Side Effects Reported” Is Not “No Side Effects”

Many online claims that BPC-157 has no side effects rely on the absence of reports. But side effects can only be reported if studies are designed to look for them, include enough people and run long enough. With two people in a pilot study and a handful in uncontrolled reports, uncommon side effects, or ones that take time to appear, would almost certainly be missed. For comparison, the side effects of the GLP-1 medicines only became clear through trials involving thousands of participants over more than a year (PMID: 33567185). That is the scale of evidence needed to say a compound’s side effects are known.

How Safety Would Be Established

If BPC-157 were to be developed as a medicine, its safety would be established through formal toxicology in two animal species, detailed pharmacokinetic studies, and a series of human trials of increasing size, with every adverse event recorded and compared with placebo. Long-term follow-up would look for effects that appear only over time. Until that work is done and published, statements about its human safety profile remain provisional.

What Researchers Measure in BPC-157 Studies

Safety readouts

Well-designed studies record body weight, food intake, behaviour and organ appearance, and measure blood markers of liver, kidney and heart function, as the 2025 pilot did.

Mechanism readouts

Blood vessel density, VEGFR2 signalling, inflammatory markers and tissue repair measures link the compound’s effects to its proposed mechanisms.

Controls

Vehicle controls, which receive everything except the compound, are essential to separate real effects from the effects of handling and diluent.

The Technical Breakdown: Mechanisms Behind the Open Questions

VEGFR2

VEGFR2 is a receptor tyrosine kinase on the cells lining blood vessels. When activated, it drives those cells to multiply, migrate and form new vessels. It is essential for wound healing and also a well-known target in cancer biology, where blocking it is used to starve tumours. That dual role is exactly why BPC-157’s effect on it raises both interest and questions.

Nitric oxide

Animal research has repeatedly linked BPC-157 to the nitric oxide system, which regulates blood vessel tone and blood flow. Effects on this system could, in principle, influence blood pressure and circulation.

Stability

BPC-157’s stability in gastric juice is unusual for a peptide and part of why it has been studied by several routes in animals. It also means it may persist differently from most peptides, which is relevant to understanding its effects.

Immunogenicity

Any peptide can, in principle, trigger an immune response, especially if impure or aggregated. The FDA’s 2023 concerns included this possibility, which has not been studied in people.

BPC-157 in Combination: A Further Unknown

BPC-157 is frequently discussed alongside other peptides, most often TB-500, and it appears in several multi-peptide blends. Combinations add another layer of uncertainty to the safety question, because two compounds together can behave differently from either alone. The small 2021 knee pain report included some patients who received BPC-157 together with thymosin beta-4, but it was not designed to compare safety between single and combined use. In research, the clearest way to study combinations is a four-arm design comparing a control, each compound alone and the combination, so that any effect of combining them can be seen. Our article peptide stacking in research explains how combination studies are designed.

What Researchers Would Want to Monitor

For laboratory and animal research, the open questions about BPC-157 translate into practical measurements. Blood vessel density in treated tissues, markers of cell proliferation, blood pressure and heart rate, liver and kidney markers, body weight and behaviour all help build a picture of its effects beyond the intended one. Including these measures in studies designed mainly to test healing would steadily add to what is known about its wider profile, even before any formal toxicology programme is undertaken.

The Research Community’s View

Across the reviews published in 2025, a consistent picture emerges. Researchers are genuinely interested in BPC-157, because its animal findings across so many tissues are unusual and intriguing. At the same time, they are clear that interest is running well ahead of evidence. The HSS Journal systematic review found very few human studies of any kind, and the “Regeneration or Risk?” review argued that proper clinical trials are needed before the balance of benefit and risk in people can be judged. Both reviews emphasised that the regulatory status of BPC-157, and the variable quality of products available outside regulated channels, add further uncertainty. That balanced view, interest combined with caution, is where the scientific consensus currently sits.

Why Verified Material Matters

For research, the first safety question is whether the compound is what it claims to be. Every batch of BPC-157 supplied by Crown Peptides comes with a batch-specific certificate of analysis showing HPLC purity and mass spectrometry identity, with lot numbers matching vial labels. Published certificates are on our Lab Reports page, and our guides to peptide testing and how to tell if peptides are real explain the methods.

Related Compounds and Reading

BPC-157 is often studied alongside TB-500, including in the Wolverine Stack (BPC-157 + TB-500 Blend), and in the blends GLOW and KLOW, and the Gastrointestinal Research Bundle. Read BPC-157 vs TB-500 and are peptides safe for wider context, and browse the tissue biology research peptides category.

BPC-157 Side Effects: Questions, Answered

Does BPC-157 have side effects?

Its side effect profile in people is not established. Animal studies have generally reported no obvious toxicity, and a two-person pilot reported no side effects, but there are no large or long-term human trials.

Is BPC-157 safe?

Its safety in humans has not been demonstrated by controlled trials. Reviews describe promising preclinical findings alongside unresolved safety questions.

Can BPC-157 affect the liver or heart?

The 2025 pilot measured liver and heart markers in two people and found no measurable changes, but that is far too small to draw firm conclusions.

Does BPC-157 cause cancer?

There is no evidence that it does. Because it promotes blood vessel growth, reviewers have raised the theoretical question of whether it could support existing unwanted growth, which has not been studied in long-term human research.

What would make BPC-157’s safety clearer?

Formal toxicology studies followed by randomised, placebo-controlled human trials of adequate size and length, using verified material, with independent replication.

Can BPC-157 cause an immune reaction?

Any peptide can, in principle, trigger an immune response, particularly if it is impure or has clumped together. The FDA cited this possibility in 2023. It has not been studied in controlled human research.

How can researchers make sure they are studying real BPC-157?

By using material with a batch-specific certificate of analysis showing HPLC purity and mass spectrometry identity, with a lot number matching the vial.

What do recent reviews conclude about BPC-157?

That its preclinical findings are promising, that human evidence is very limited, and that well-designed clinical trials are needed before its safety and effectiveness in people can be judged.

Does BPC-157 affect blood pressure?

Animal research has linked BPC-157 to the nitric oxide system, which helps regulate blood vessel tone, but its effects on blood pressure in people have not been studied in controlled trials.

Is BPC-157 approved as a medicine anywhere?

It is not a licensed medicine in the UK, and no regulator has approved it for therapeutic use. The July 2026 FDA advisory committee vote was a recommendation about compounding pharmacy access, not an approval.

Are there human trials of BPC-157?

There are no large, published randomised controlled trials. Human evidence consists of a two-person pilot safety study and small uncontrolled reports.

Why do online reports of side effects vary so much?

Because they describe products of unknown quality, used in unknown ways, without any control group, so they cannot separate the effects of BPC-157 from impurities, other factors or chance.

Is oral BPC-157 different from other forms?

BPC-157 has been studied by several routes in animals, helped by its unusual stability in gastric juice. How different routes compare for safety in people has not been studied.

Why is BPC-157 banned in sport?

WADA lists it as a non-approved substance, a category covering compounds that no regulator has approved for therapeutic use.

What We Know, and What We Do Not

BPC-157 has one of the most extensive animal research records of any research peptide, and that research is genuinely intriguing. But its human safety story is still mostly unwritten: a pilot study of two people, a few uncontrolled reports and a set of reasonable open questions that only proper trials can answer. Anyone telling you it has no side effects is claiming more than the evidence can support, and anyone telling you it is dangerous is doing the same. The honest position is that the research is promising and the human data are thin.

For laboratory research, start with verified material. Explore BPC-157 from Crown Peptides, supplied as a laboratory research material, every batch HPLC and mass spectrometry verified and dispatched from the UK.